Symbols / SCNI Stock $0.60 +0.75% Scinai Immunotherapeutics Ltd.
SCNI (Stock) Chart
About
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufacturing organization services to biotech companies. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.93M |
| Enterprise Value | 8.33B | Income | -8.31M | Sales | 1.31M |
| Book/sh | 1.47 | Cash/sh | 1661000.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | inf | Forward P/E | — | PEG | — |
| P/S | 1.47 | P/B | 0.41 | P/C | — |
| EV/EBITDA | -1360.88 | EV/Sales | 6353.91 | Quick Ratio | 1.09 |
| Current Ratio | 1.30 | Debt/Eq | 27.98 | LT Debt/Eq | — |
| EPS (ttm) | 0.00 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | 30.60% | Earnings | 2024-05-15 16:00 | ROA | -37.60% |
| ROE | -91.89% | ROIC | — | Gross Margin | -202.29% |
| Oper. Margin | -7.02% | Profit Margin | 0.00% | Shs Outstand | 3.19M |
| Shs Float | 12.25B | Short Float | 2.17% | Short Ratio | 1.45 |
| Short Interest | — | 52W High | 6.18 | 52W Low | 0.55 |
| Beta | — | Avg Volume | 54.15K | Volume | 65.20K |
| Target Price | — | Recom | None | Prev Close | $0.60 |
| Price | $0.60 | Change | 0.75% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
- Scinai splits drug research from manufacturing, aims for $5M in 2026 CDMO sales - Stock Titan Mon, 06 Apr 2026 11
- Quarterly Recap: Is SCNI stock good for income investors - Quarterly Investment Review & AI Driven Stock Reports - baoquankhu1.vn Mon, 06 Apr 2026 14
- Scinai completes strategic reorganization to establish dedicated CDMO platform and lean R&D structure; outlines 2026 priorities - marketscreener.com Mon, 06 Apr 2026 11
- Scinai doubled revenue, then bought a Recipharm site in Israel - Stock Titan Wed, 01 Apr 2026 11
- Scinai 2025 Rev $1.3M >SCNI - Moomoo Wed, 01 Apr 2026 11
- Scinai Immunotherapeutics (NASDAQ: SCNI) details going concern, CDMO and NanoAb risks - Stock Titan Wed, 01 Apr 2026 11
- Scinai Immunotherapeutics (SCNI) director reports sizable stock option positions - Stock Titan Wed, 18 Mar 2026 07
- If You Invested $1,000 in Scinai Immunotherapeutics Ltd. (SCNI) - Stock Titan Mon, 23 Mar 2026 06
- Scinai Immunotherapeutics (SCNI) COO discloses major equity stake - Stock Titan hu, 26 Mar 2026 07
- Scinai stock falls under Nasdaq’s $1 rule, 180 days to fix - Stock Titan Mon, 16 Mar 2026 07
- After its Recipharm deal, Scinai takes expanded drug-making pitch to Europe - Stock Titan hu, 19 Mar 2026 07
- Scinai Immunotherapeutics (SCNI) director discloses ADS and option holdings - Stock Titan Wed, 18 Mar 2026 07
- Green Jay discloses Scinai Immunotherapeutics (SCNI) ADS and option holdings - Stock Titan Wed, 18 Mar 2026 07
- Scinai Immunotherapeutics (SCNI) director reports ADS and large option holdings - Stock Titan Wed, 18 Mar 2026 07
- Scinai Immunotherapeutics (SCNI) director reports ADS and option holdings - Stock Titan Wed, 18 Mar 2026 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
1.31
+99.24%
|
0.66
|
0.00
|
0.00
|
| Operating Revenue |
|
1.31
+99.24%
|
0.66
|
0.00
|
0.00
|
| Cost Of Revenue |
|
3.96
+220.11%
|
1.24
|
0.00
|
0.00
|
| Reconciled Cost Of Revenue |
|
3.96
+220.11%
|
1.24
|
0.00
|
0.00
|
| Gross Profit |
|
-2.65
-357.24%
|
-0.58
|
0.00
|
0.00
|
| Operating Expense |
|
4.89
-39.31%
|
8.06
-16.98%
|
9.71
-12.25%
|
11.06
|
| Research And Development |
|
2.37
-57.18%
|
5.53
+6.18%
|
5.21
-9.63%
|
5.76
|
| Selling General And Administration |
|
2.52
-0.20%
|
2.53
-43.93%
|
4.50
-14.94%
|
5.30
|
| General And Administrative Expense |
|
—
|
—
|
—
|
—
|
| Salaries And Wages |
|
—
|
—
|
—
|
—
|
| Other Gand A |
|
—
|
—
|
—
|
—
|
| Other Operating Expenses |
|
—
|
—
|
-0.01
|
—
|
| Total Expenses |
|
8.85
-4.77%
|
9.30
-4.22%
|
9.71
-12.25%
|
11.06
|
| Operating Income |
|
-7.54
+12.69%
|
-8.64
+11.00%
|
-9.71
+12.25%
|
-11.06
|
| Total Operating Income As Reported |
|
-7.54
+12.69%
|
-8.64
+11.00%
|
-9.71
+12.25%
|
-11.06
|
| EBITDA |
|
-6.53
-182.97%
|
7.87
+460.05%
|
-2.19
+58.25%
|
-5.23
|
| Normalized EBITDA |
|
-6.11
+11.42%
|
-6.90
-30.76%
|
-5.28
+29.36%
|
-7.47
|
| Reconciled Depreciation |
|
1.42
-13.83%
|
1.65
+220.82%
|
0.51
-8.54%
|
0.56
|
| EBIT |
|
-7.95
-227.82%
|
6.22
+330.38%
|
-2.70
+53.43%
|
-5.80
|
| Total Unusual Items |
|
-0.42
-102.82%
|
14.77
+377.71%
|
3.09
+38.30%
|
2.23
|
| Total Unusual Items Excluding Goodwill |
|
-0.42
-102.82%
|
14.77
+377.71%
|
3.09
+38.30%
|
2.23
|
| Special Income Charges |
|
0.00
-100.00%
|
14.76
|
0.00
|
0.00
|
| Other Special Charges |
|
—
|
-14.76
|
—
|
—
|
| Net Income |
|
-8.31
-273.21%
|
4.80
+173.78%
|
-6.50
-12.15%
|
-5.80
|
| Pretax Income |
|
-8.31
-273.21%
|
4.80
+173.78%
|
-6.50
-12.15%
|
-5.80
|
| Net Non Operating Interest Income Expense |
|
-0.35
+73.80%
|
-1.33
-1258.26%
|
0.12
-96.20%
|
3.03
|
| Interest Expense Non Operating |
|
0.36
-74.75%
|
1.42
-62.59%
|
3.80
|
0.00
|
| Net Interest Income |
|
-0.35
+73.80%
|
-1.33
-1258.26%
|
0.12
-96.20%
|
3.03
|
| Interest Expense |
|
0.36
-74.75%
|
1.42
-62.59%
|
3.80
|
0.00
|
| Interest Income Non Operating |
|
0.02
-80.00%
|
0.10
-97.45%
|
3.92
+28.61%
|
3.05
|
| Interest Income |
|
0.02
-80.00%
|
0.10
-97.45%
|
3.92
+28.61%
|
3.05
|
| Other Income Expense |
|
-0.42
-102.82%
|
14.77
+377.71%
|
3.09
+38.30%
|
2.23
|
| Gain On Sale Of Security |
|
-0.42
-6042.86%
|
0.01
-99.77%
|
3.09
+38.30%
|
2.23
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
-100.00%
|
3.40
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-8.31
-273.21%
|
4.80
+173.78%
|
-6.50
-12.15%
|
-5.80
|
| Net Income From Continuing Operation Net Minority Interest |
|
-8.31
-273.21%
|
4.80
+173.78%
|
-6.50
-12.15%
|
-5.80
|
| Net Income From Continuing And Discontinued Operation |
|
-8.31
-273.21%
|
4.80
+173.78%
|
-6.50
-12.15%
|
-5.80
|
| Net Income Continuous Operations |
|
-8.31
-273.21%
|
4.80
+173.78%
|
-6.50
-12.15%
|
-5.80
|
| Normalized Income |
|
-7.89
-20.04%
|
-6.57
+31.46%
|
-9.59
-19.42%
|
-8.03
|
| Net Income Common Stockholders |
|
0.00
|
0.00
+100.00%
|
-6.50
-12.15%
|
-5.80
|
| Diluted EPS |
|
—
|
0.00
+100.00%
|
-16.00
+60.00%
|
-40.00
|
| Basic EPS |
|
—
|
0.00
+100.00%
|
-16.00
+60.00%
|
-40.00
|
| Basic Average Shares |
|
—
|
0.81
+106.41%
|
0.39
+107.22%
|
0.19
|
| Diluted Average Shares |
|
—
|
0.81
+106.41%
|
0.39
+107.22%
|
0.19
|
| Diluted NI Availto Com Stockholders |
|
0.00
|
0.00
+100.00%
|
-6.50
-12.15%
|
-5.80
|
| Depreciation Amortization Depletion Income Statement |
|
—
|
—
|
—
|
—
|
| Depreciation And Amortization In Income Statement |
|
—
|
—
|
—
|
—
|
| Depreciation Income Statement |
|
—
|
—
|
—
|
—
|
| Preferred Stock Dividends |
|
-8.31
-273.21%
|
4.80
|
—
|
—
|
| Rent And Landing Fees |
|
—
|
—
|
—
|
—
|
| Rent Expense Supplemental |
|
—
|
—
|
—
|
—
|
| Total Other Finance Cost |
|
0.01
+0.00%
|
0.01
+25.00%
|
0.01
-61.90%
|
0.02
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
11.63
-13.55%
|
13.45
-23.03%
|
17.47
-35.45%
|
27.07
|
| Current Assets |
|
2.05
-14.09%
|
2.39
-56.10%
|
5.45
-62.09%
|
14.37
|
| Cash Cash Equivalents And Short Term Investments |
|
1.66
-15.43%
|
1.96
-59.67%
|
4.87
-65.40%
|
14.07
|
| Cash And Cash Equivalents |
|
1.66
-15.43%
|
1.96
-59.67%
|
4.87
-65.40%
|
14.07
|
| Cash Financial |
|
—
|
—
|
—
|
—
|
| Receivables |
|
0.17
-22.58%
|
0.22
-40.71%
|
0.37
+232.73%
|
0.11
|
| Accounts Receivable |
|
0.07
-12.05%
|
0.08
|
0.00
|
—
|
| Other Receivables |
|
0.10
-29.10%
|
0.13
-63.39%
|
0.37
+232.73%
|
0.11
|
| Prepaid Assets |
|
0.07
-5.06%
|
0.08
+11.27%
|
0.07
+57.78%
|
0.04
|
| Restricted Cash |
|
0.15
+14.50%
|
0.13
-6.43%
|
0.14
+0.00%
|
0.14
|
| Total Non Current Assets |
|
9.57
-13.43%
|
11.06
-8.05%
|
12.03
-5.29%
|
12.70
|
| Net PPE |
|
9.57
-13.43%
|
11.06
-8.05%
|
12.03
-5.29%
|
12.70
|
| Gross PPE |
|
15.45
-0.42%
|
15.51
+4.58%
|
14.83
-1.89%
|
15.12
|
| Accumulated Depreciation |
|
-5.88
-31.87%
|
-4.46
-58.69%
|
-2.81
-15.99%
|
-2.42
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
—
|
—
|
—
|
—
|
| Machinery Furniture Equipment |
|
7.78
+0.06%
|
7.77
+2321.18%
|
0.32
-3.31%
|
0.33
|
| Construction In Progress |
|
—
|
0.00
-100.00%
|
7.45
-4.90%
|
7.83
|
| Other Properties |
|
3.95
-1.74%
|
4.02
+20.23%
|
3.34
+9.93%
|
3.04
|
| Leases |
|
3.72
+0.00%
|
3.72
+0.00%
|
3.72
-4.90%
|
3.92
|
| Other Non Current Assets |
|
—
|
—
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
3.52
+1.50%
|
3.47
-84.25%
|
22.04
-23.54%
|
28.83
|
| Current Liabilities |
|
1.58
-12.24%
|
1.81
+1.46%
|
1.78
-23.87%
|
2.34
|
| Payables And Accrued Expenses |
|
1.17
+0.78%
|
1.16
-16.40%
|
1.38
-29.24%
|
1.96
|
| Payables |
|
0.41
+8.24%
|
0.38
-29.72%
|
0.54
-25.28%
|
0.72
|
| Accounts Payable |
|
0.41
+8.24%
|
0.38
-29.72%
|
0.54
-25.28%
|
0.72
|
| Current Accrued Expenses |
|
0.76
-2.82%
|
0.78
-8.01%
|
0.85
-31.53%
|
1.24
|
| Employee Benefits |
|
—
|
—
|
—
|
—
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
—
|
—
|
—
|
0.48
|
| Current Debt And Capital Lease Obligation |
|
0.33
-22.41%
|
0.42
+7.07%
|
0.40
+3.66%
|
0.38
|
| Current Capital Lease Obligation |
|
0.33
-22.41%
|
0.42
+7.07%
|
0.40
+3.66%
|
0.38
|
| Current Deferred Liabilities |
|
0.09
-60.00%
|
0.23
|
0.00
|
—
|
| Current Deferred Revenue |
|
0.09
-60.00%
|
0.23
|
0.00
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
1.94
+16.40%
|
1.67
-91.78%
|
20.26
-23.51%
|
26.49
|
| Long Term Debt And Capital Lease Obligation |
|
1.94
+16.61%
|
1.66
-91.76%
|
20.16
-4.70%
|
21.16
|
| Long Term Debt |
|
0.29
+13.08%
|
0.26
-98.66%
|
19.37
-3.56%
|
20.08
|
| Long Term Capital Lease Obligation |
|
1.64
+17.26%
|
1.40
+75.91%
|
0.80
-26.07%
|
1.08
|
| Non Current Pension And Other Postretirement Benefit Plans |
|
—
|
—
|
—
|
—
|
| Tradeand Other Payables Non Current |
|
—
|
—
|
—
|
—
|
| Stockholders Equity |
|
8.10
-18.78%
|
9.98
+318.36%
|
-4.57
-159.60%
|
-1.76
|
| Common Stock Equity |
|
2.48
-43.08%
|
4.35
+195.21%
|
-4.57
-159.60%
|
-1.76
|
| Capital Stock |
|
5.63
+0.00%
|
5.63
|
0.00
|
0.00
|
| Common Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Preferred Stock |
|
5.63
+0.00%
|
5.63
|
0.00
|
—
|
| Share Issued |
|
6,056.62
+77.51%
|
3,411.98
+83.72%
|
1,857.17
+87.73%
|
989.29
|
| Ordinary Shares Number |
|
6,056.62
+77.51%
|
3,411.98
+83.72%
|
1,857.17
+87.73%
|
989.29
|
| Additional Paid In Capital |
|
130.06
+5.20%
|
123.63
+3.45%
|
119.51
+2.95%
|
116.08
|
| Retained Earnings |
|
-125.85
-7.07%
|
-117.54
+3.92%
|
-122.33
-5.61%
|
-115.83
|
| Gains Losses Not Affecting Retained Earnings |
|
-1.74
+0.00%
|
-1.74
+0.00%
|
-1.74
+13.30%
|
-2.01
|
| Other Equity Adjustments |
|
-1.74
+0.00%
|
-1.74
+0.00%
|
-1.74
+13.30%
|
-2.01
|
| Total Equity Gross Minority Interest |
|
8.10
-18.78%
|
9.98
+318.36%
|
-4.57
-159.60%
|
-1.76
|
| Total Capitalization |
|
8.40
-17.97%
|
10.24
-30.83%
|
14.80
-19.23%
|
18.32
|
| Working Capital |
|
0.47
-19.83%
|
0.58
-84.05%
|
3.67
-69.52%
|
12.03
|
| Invested Capital |
|
2.77
-39.91%
|
4.61
-68.85%
|
14.80
-19.23%
|
18.32
|
| Total Debt |
|
2.27
+8.68%
|
2.09
-89.85%
|
20.56
-4.55%
|
21.54
|
| Net Debt |
|
—
|
—
|
14.50
+141.35%
|
6.01
|
| Capital Lease Obligations |
|
1.97
+8.05%
|
1.83
+53.06%
|
1.19
-18.29%
|
1.46
|
| Net Tangible Assets |
|
8.10
-18.78%
|
9.98
+318.36%
|
-4.57
-159.60%
|
-1.76
|
| Tangible Book Value |
|
2.48
-43.08%
|
4.35
+195.21%
|
-4.57
-159.60%
|
-1.76
|
| Derivative Product Liabilities |
|
0.00
-100.00%
|
0.00
-96.88%
|
0.10
-98.20%
|
5.33
|
| Preferred Stock Equity |
|
5.63
+0.00%
|
5.63
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-6.03
+4.80%
|
-6.33
+32.48%
|
-9.38
-29.14%
|
-7.26
|
| Cash Flow From Continuing Operating Activities |
|
-6.03
+4.80%
|
-6.33
+32.48%
|
-9.38
-29.14%
|
-7.26
|
| Net Income From Continuing Operations |
|
-8.31
-273.21%
|
4.80
+173.78%
|
-6.50
-12.15%
|
-5.80
|
| Depreciation Amortization Depletion |
|
1.42
-13.83%
|
1.65
+220.82%
|
0.51
-8.54%
|
0.56
|
| Depreciation |
|
1.42
-13.83%
|
1.65
+220.82%
|
0.51
-8.54%
|
0.56
|
| Depreciation And Amortization |
|
1.42
-13.83%
|
1.65
+220.82%
|
0.51
-8.54%
|
0.56
|
| Other Non Cash Items |
|
0.39
+102.91%
|
-13.48
-3461.85%
|
0.40
+110.27%
|
-3.90
|
| Pension And Employee Benefit Expense |
|
—
|
—
|
—
|
—
|
| Stock Based Compensation |
|
0.30
-55.57%
|
0.68
-40.12%
|
1.14
-28.90%
|
1.60
|
| Operating Gains Losses |
|
-0.00
+96.77%
|
-0.09
+97.75%
|
-4.14
|
—
|
| Gain Loss On Investment Securities |
|
-0.00
+96.77%
|
-0.09
+97.75%
|
-4.14
|
—
|
| Change In Working Capital |
|
0.16
+45.54%
|
0.11
+114.07%
|
-0.80
-393.73%
|
0.27
|
| Change In Receivables |
|
0.05
-62.41%
|
0.14
+148.62%
|
-0.29
-307.14%
|
0.14
|
| Changes In Account Receivables |
|
0.01
+112.05%
|
-0.08
|
0.00
|
—
|
| Change In Payables And Accrued Expense |
|
-0.13
-12700.00%
|
0.00
+100.20%
|
-0.49
-466.42%
|
0.13
|
| Change In Payable |
|
-0.13
-12700.00%
|
0.00
+100.20%
|
-0.49
-466.42%
|
0.13
|
| Change In Account Payable |
|
0.03
+119.87%
|
-0.16
-4.00%
|
-0.15
+14.29%
|
-0.17
|
| Change In Other Current Assets |
|
0.09
-68.66%
|
0.28
+560.47%
|
0.04
-71.90%
|
0.15
|
| Change In Other Current Liabilities |
|
0.15
+146.82%
|
-0.31
-441.38%
|
-0.06
+62.82%
|
-0.16
|
| Investing Cash Flow |
|
-0.02
-100.00%
|
-0.01
+98.12%
|
-0.64
+23.80%
|
-0.84
|
| Cash Flow From Continuing Investing Activities |
|
-0.02
-100.00%
|
-0.01
+98.12%
|
-0.64
+23.80%
|
-0.84
|
| Net PPE Purchase And Sale |
|
-0.02
-100.00%
|
-0.01
+98.12%
|
-0.64
+23.80%
|
-0.84
|
| Purchase Of PPE |
|
-0.02
-100.00%
|
-0.01
+98.12%
|
-0.64
+23.80%
|
-0.84
|
| Sale Of PPE |
|
—
|
—
|
—
|
—
|
| Capital Expenditure |
|
-0.02
-100.00%
|
-0.01
+98.12%
|
-0.64
+23.80%
|
-0.84
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
—
|
| Financing Cash Flow |
|
5.77
+67.68%
|
3.44
+216.85%
|
1.09
-83.97%
|
6.78
|
| Cash Flow From Continuing Financing Activities |
|
5.77
+67.68%
|
3.44
+216.85%
|
1.09
-83.97%
|
6.78
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
—
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Repayment Of Debt |
|
—
|
—
|
—
|
—
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
—
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
5.77
+188.50%
|
2.00
+1338.85%
|
0.14
-85.09%
|
0.93
|
| Proceeds From Stock Option Exercised |
|
—
|
1.44
+52.16%
|
0.95
-83.80%
|
5.84
|
| Changes In Cash |
|
-0.28
+90.19%
|
-2.91
+67.47%
|
-8.93
-574.19%
|
-1.32
|
| Effect Of Exchange Rate Changes |
|
0.00
+111.11%
|
-0.01
+96.69%
|
-0.27
+86.24%
|
-1.98
|
| Beginning Cash Position |
|
2.10
-58.18%
|
5.01
-64.76%
|
14.21
-18.85%
|
17.52
|
| End Cash Position |
|
1.81
-13.56%
|
2.10
-58.18%
|
5.01
-64.76%
|
14.21
|
| Free Cash Flow |
|
-6.05
+4.60%
|
-6.35
+36.65%
|
-10.02
-23.68%
|
-8.10
|
| Interest Paid Supplemental Data |
|
0.00
-100.00%
|
0.14
-82.83%
|
0.83
-9.06%
|
0.92
|
| Common Stock Issuance |
|
5.77
+188.50%
|
2.00
+1338.85%
|
0.14
-85.09%
|
0.93
|
| Interest Paid CFO |
|
—
|
—
|
—
|
—
|
| Interest Received CFO |
|
—
|
—
|
—
|
—
|
| Issuance Of Capital Stock |
|
5.77
+188.50%
|
2.00
+1338.85%
|
0.14
-85.09%
|
0.93
|
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|